These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34496769)

  • 1. Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study.
    Taniyama Y; Murakami K; Yoshida N; Takahashi K; Matsubara H; Baba H; Kamei T
    BMC Cancer; 2021 Sep; 21(1):1008. PubMed ID: 34496769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral
    Yamamura K; Izumi D; Kandimalla R; Sonohara F; Baba Y; Yoshida N; Kodera Y; Baba H; Goel A
    Clin Cancer Res; 2019 Oct; 25(20):6170-6179. PubMed ID: 31358543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
    J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Pathological Tumor Regression and Nodal Status on Survival and Systemic Disease in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Miyata H; Tanaka K; Makino T; Yamasaki M; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Morii E; Mori M; Doki Y
    Ann Surg Oncol; 2018 Aug; 25(8):2409-2417. PubMed ID: 29748887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
    Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
    Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes according to the modified endoscopic criteria for neoadjuvant chemotherapy in resectable esophageal squamous cell carcinoma.
    Kadota T; Abe S; Yoda Y; Yoshinaga S; Oda I; Kojima T; Kato K; Daiko H; Yano T
    Dig Endosc; 2020 Mar; 32(3):337-345. PubMed ID: 31295769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer.
    Kano K; Aoyama T; Yoshikawa T; Maezawa Y; Nakajima T; Hayashi T; Yamada T; Sato T; Oshima T; Rino Y; Masuda M; Cho H; Ogata T
    Ann Surg Oncol; 2018 Jul; 25(7):2034-2043. PubMed ID: 29748890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.
    Takeuchi M; Kawakubo H; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2019 Jul; 26(7):2081-2089. PubMed ID: 30937664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
    Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
    Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
    Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H
    Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma.
    Miyata H; Sugimura K; Motoori M; Omori T; Yamamoto K; Yanagimoto Y; Shinno N; Yasui M; Takahashi H; Wada H; Ohue M; Yano M
    Ann Surg Oncol; 2019 Dec; 26(13):4737-4743. PubMed ID: 31414291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patients.
    Buck A; Prade VM; Kunzke T; Feuchtinger A; Kröll D; Feith M; Dislich B; Balluff B; Langer R; Walch A
    J Pathol; 2022 Feb; 256(2):202-213. PubMed ID: 34719782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma.
    Kauppila JH; Wahlin K; Lagergren P; Lagergren J
    Int J Cancer; 2019 Mar; 144(6):1284-1291. PubMed ID: 30168595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan.
    Kaida H; Kitajima K; Nakajo M; Ishibashi M; Matsunaga T; Minamimoto R; Hirata K; Nakatani K; Hung A; Hattori S; Yasuda T; Ishii K
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3666-3682. PubMed ID: 33934168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of response evaluation for resectable esophageal adenocarcinoma - a retrospective cohort study.
    Bachmann R; Bachmann J; Hungbauer A; Schmehl J; Sitzmann G; Königsrainer A; Ladurner R
    Int J Surg; 2014 Oct; 12(10):1025-30. PubMed ID: 25192805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.